Melanoma resistance to combination BRAF and MEK inhibition is driven by reprogramming of MAPK signaling [ 2014 - 2016 ]

Research Grant

Researchers: Prof Helen Rizos (Principal investigator) ,  Prof Georgina Long ,  Prof Richard Kefford

Brief description Until recently, patients with metastatic melanoma were treated with single agent chemotherapy drugs that produce response rates of less than 10%. New drugs targeting the mitogen activated protein kinase (MAPK) pathway have now shown significant activity, but nearly all patients treated with these new inhibitors eventually develop resistance and progress. This project utilises patient tumour samples to examine the mechanisms of resistance and ways of enhancing the targeted inhibition of the MAPK signaling cascade.

Funding Amount $AUD 745,082.48

Funding Scheme Project Grants

Notes Standard Project Grant